Iovance
IOVAMarket price data through October 2, 2026.
Performance
Oct 2021 – Oct 2026
Track record
How this pick has done since Benson first called it.
- Benson Return
- 0%
- How much this stock is up since Benson first picked it — measured from the price at the time of that first pick, not from today.
- First pick price
- ~$14
- Roughly what one share cost when Benson first picked this stock. This is the starting line for the Benson Return.
- Tracking since
- October 2026
- The month this stock first became a Benson pick.
- Tracking duration
- 0 months
- How long Benson has been tracking this pick.
About Iovance
Iovance makes Amtagvi, a one-time cancer treatment built from a patient's own immune cells. Think of it as taking the body's best fighters out of the tumor, training an army of them in a lab, and sending them back in. It is the first treatment of its kind approved for advanced melanoma.
The case for and against
Both sides of the story, in plain English.
- Sales Are Surging
Revenue hit 99 million dollars last quarter, up 66% from a year earlier, with a record 56% gross margin. Management just raised its 2026 revenue target to 410 to 420 million dollars, which implies nearly 60% growth for the year.
- Lung Cancer Upside
Early lung cancer results showed a 26% response rate versus about 13% for standard chemotherapy. The company says lung cancer is roughly seven times bigger than melanoma, so success there could multiply the business.
- Still Burning Cash
Iovance lost 47 million dollars last quarter, and net margins are negative 89%. It keeps selling new shares to pay the bills, and the share count has climbed from about 335 million to about 450 million in a year.
- Priced For Success
The stock has gone from under 2 dollars to around 15 dollars in a year, and the company is worth about 6 billion dollars. It relies mostly on one product, so a trial setback or a new competing treatment could hit the price hard.
Other companies we track
How to read this page
This automated research summary uses Financial Modeling Prep market data through 2026-10-02. Model signals, scores, and risk labels can change and may be incomplete or wrong.
Want Benson to watch IOVA for you?
Get the app to follow every Benson pick live — and let Benson do the research for you.
Download on the App Store
Download Android app